CEND-1 + gemcitabine/nab-paclitaxel

Indication // Pancreatic ductal adenocarcinoma (PDAC)

Pancreatic cancer represents a high unmet medical need. Current standard-of-care chemotherapy is limited by poor ability to target and penetrate dense tumor stroma. Based on encouraging Phase 1 clinical trial results, Cend is advancing development to more effectively target and treat PDAC.

CEND-1 + SoC chemo + anti-PD(L)1

Indication // Pancreatic ductal adenocarcimona (PDAC)

Effectiveness of immunotherapies, including checkpoint inhibitor antibody drugs, has been limited by poor ability to penetrate PDAC stroma and an immunosuppressive tumor microenvironment. Cend is advancing development to enhance penetration of checkpoint inhibitors and targeted depletion of tumor-infiltrating immunosuppressive cells to enhance effectiveness of immunotherapy in combination with chemotherapy.

CEND-1 + SoC

Indication // Triple negative breast cancer (TNBC)

Cend’s treatment approach may enhance ability to target and penetrate a range of solid tumor cancer types as well as reduce their immunosuppressive tumor microenvironments to enable the patients’ immune systems and/or immunotherapies to more effectively fight their cancers.

Ras pathway modulator

Indication // PDAC / other Ras-driven cancers

Over 90% of pancreatic cancers are driven by dysregulation of Ras and the MAPK pathway. Cend is advancing a program to address resistance mechanism associated with other Ras-targeted approaches.